Anne Whitaker Appointed as Non-Executive Director
Ms. Whitaker is an accomplished C-suite leader, most recently as Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline ...
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...
Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) ...
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
WEREWOLF ®, the WEREWOLF logo, PREDATOR ®, INDUKINE ™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, ...
Le Lézard4d
Human Frontier Science Program: Fellowships Awarded to 60 Pioneering Postdoctoral Scientists from 25 Nations
To foster the next generation of life science research, 60 of the world's top emerging scientists from 25 nations have won 2025 Human Frontier Science Program (HFSP) Fellowships. "We have awarded ...